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1. Introduction 
Neurodegenerative diseases are pathological processes characterized by neuronal death and 
morbid evolution leading to occupational injury and serious neuropsychiatric disorders. The 
natural course of neurodegenerative diseases does not show regression of symptoms or cure 
and current treatments are far from producing a real improvement in the quality of patient’s 
life. Several studies have been conducted in an attempt to find causes of cellular 
disturbances focusing new pharmacological targets priming to successful therapeutic 
interventions. Studies have been directed to investigate possible changes in energy 
metabolism pathways. Indeed, some disturbances in glycolytic pathway and mitochondrial 
dysfunctions have been associated with Huntington’s Disease and other neurodegenerative 
diseases and are often related to the events of cell death. In this section, an overview of the 
energy metabolism pathways will be presented and the particular aspects of energetic 
metabolism in Huntington’s Disease will be discussed. 
2. Glucose transport 
Under ordinary conditions, the basic substrate for brain metabolism is glucose. In the resting 
state, adults use about 20% of whole-body glucose for brain metabolism. The brain has an 
exquisite dependence on glucose for energy production and as an important carbon source 
for biosynthesis of a variety of simple and complex molecules (Siegel et al., 1999). Such 
dependence is well demonstrated and a transient decline in the metabolism of glucose 
would cause a serious disruption of brain function (Oliveira et al., 2007). As glucose is a 
water-soluble substance its entry into brain from blood is greatly restricted (Vannucci et al., 
1997). The major reason for that is the presence of an anatomical-physiological barrier – so 
called Blood-Brain-Barrier (BBB). The BBB is a specialized barrier made up of microvascular 
endothelial cells that are held together by tight junction complexes that effectively avoid the 
paracellular diffusion of solutes (Wilhelm et al., 2011). Even small molecules do not simply 
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diffuse across this physical barrier. To manage this problem, not only for glucose but also 
for other metabolites important to brain metabolism, there are a large family of specific 
membrane transporters responsible to carry these molecules across the BBB by means of 
facilitated diffusion through the luminal and ablumenal endothelial membranes (Vannucci 
et al., 1997).  
It is established that transport and uptake of glucose is performed by a super-family of 
glucose transporters belonging to the GLUT gene family. The GLUT family includes 12 
genes encoding 12 GLUT proteins (Vannucci et al., 1997; Klepper and Voit, 2002). Various 
members of this membrane protein family have been detected in brain (GLUT-1, GLUT-3 
and GLUT-5), but the initial glucose transport step across the BBB is mediated exclusively 
by the facilitative glucose transporter protein type 1 (GLUT-1) (Lund-Andersen, 1979; 
Pardridge et al., 1990; Klepper and Voit, 2002). Important to note is the fact that despite such 
facilitative transport mechanism, the actual concentration of glucose in brain is lower than it 
is in structures lacking a barrier, e.g. peripheral nerves. There is, then, no safety device to 
supplement carbohydrate reserve during hypoglycemia episodes making the regulation of 
GLUTs extremely relevant for brain physiology. 
Following entry into the brain glucose is transported from the interstitial fluid into neurons 
primarily via GLUT-3 and into glia primarily via GLUT-1 transporters. GLUT-5 protein is 
known to be present in brain microglia, although its function in these cells remains unclear. 
This transport into the intracellular compartment is relatively rapid, making the BBB the 
rate-limiting step for glucose entry into brain cells (Pardridge et al., 1990). 
Glucose, entering the neuronal cells, is phosphorylated irreversibly to glucose-6-phosphate 
(G-6~P) and metabolized in the pentose phosphate shunt or the Embden-Meyerhoff 
pathway, or converted to glycogen. The Embden-Meyerhoff metabolic pathway permits 
glycolytic conversion of glucose to pyruvate. Glycogen synthesis provides a source of fuel 
during periods of metabolic stress (3.3 mmol/kg rat). Evidently a decreased entry of glucose 
into the brain limits these three pathways and potentially contributes to the development of 
innumerous neuronal pathologies. 
Brain metabolic needs are demanding and the way in which it circumvents this situation has 
long remained unclear. For the past 15 years authors are looking for a more universal 
explanation but it turns out to be rather complicated. The subject is controversial and the 
field is still very active.  
Neurons and astrocytes, the two major types of brain cells, are largely responsible for the 
massive consumption of O2 and glucose in the brain. Just to point out how important they 
are, under resting conditions, astrocytes release ~85% of the glucose they consume as 
lactate. On the contrary, neurons contribute minimally to glucose consumption by the brain. 
Thus, despite their shared localization, neurons and astrocytes exhibit a different preference 
for glucose consumption and utilization (Nehlig and Coles, 2007). 
The ATP-dependent phosphorylation of glucose to G-6~P is the first step of glycolysis and it 
is catalyzed by hexokinase (HK) (Berg et al., 2006). The reaction is practically irreversible 
and has been recognized as a key point in the regulation of carbohydrate metabolism in 
brain. This whole process concomitantly generates local ADP which is important as a 
recycling mechanism. Important to note that hexokinase activity in neurons and in other cell 
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types also participates in various essential processes including ATP production, apoptosis, 
controlling glutathione levels, and preventing neuronal oxidative unbalance (Saraiva et al., 
2010). In the brain, HK-1 is the major expressed enzyme isoform. It localizes into cytosol or 
firmly attached to outer mitochondrial membrane. The bound enzyme is more active and 
the extent of binding is thought to be inversely related to the ATP/ADP ratio (Siegel et al., 
1999). Interestingly, conditions where energy utilization is greater than the substrate supply 
there is a shift in the solubilization equilibrium towards the membrane-bound enzyme form 
which per se provokes a greater potential to ignite glycolysis to meet the energy demand.  
The activity and specific subcellular localization of neuronal HK-1 are regulated by distinct 
mechanisms that act synergistically to fine-tuning glycolytic flux in response to changes in 
cellular environment. At this point it may be important to bring up the idea that 
mitochondrial-bound hexokinase 1 could be neuroprotective as has been discussed by 
different research groups in this field. 
The reaction product of HK-1 is G-6~P which represents a major branch point in metabolism 
because it is a common substrate for enzymes involved in glycolytic, pentose-phosphate 
shunt, and glycogen-forming pathways. In glycolysis, G-6~P is the substrate of isomerase 
producing fructose-6-phosphate (F-6~P). This reaction is promptly reversible (small free 
energy change), however its equilibrium ratio in brain greatly favors G-6~P accumulation. 
F-6~P is phosphorylated by phosphofructokinase-1 (PFK-1), which is considered one of the 
most regulated catalysts of the glycolytic sequence, to form fructose-1,6-bisphosphate (F-1,6-
Bis~P). As observed in other regulatory biochemical reactions it is also essentially 
irreversible.  
A number of studies focusing into this particular metabolic reaction led to the observation 
that astrocytes’ PFK-1 is about two fold more active than in neurons under baseline 
conditions (Herrero-Mendez et al., 2009). One possible reason for that is the concentration of 
fructose-2,6-bisphosphate (F-2,6-Bis~P), an powerful allosteric modulator of PFK-1 activity, 
is significantly greater in astrocytes. This dramatic difference could be ascribed to the near 
absence in neurons of phosphofructokinase-2/fructose-2,6-phosphatase (PFK-2/F-2,6-Pase) 
the bifunctional enzyme responsible for the F-2,6-Bis~P synthesis and degradation (Herrero-
Mendez et al., 2009).  
The question to be raised is how neurons actually control PFK-2/F-2,6-Pase activity? There 
are four isoforms of PFK-2/F-2,6-Pase, each encoded by a separate gene [Pfkfb1, Pfkfb2, 
Pfkfb3, and Pfkfb4] (Okar et al., 2001). It is reasonable to suppose that each isoform displays 
significantly different regulatory and kinetic features and this, in turn, determines the ratio 
of kinase/phosphatase activity, and as a consequence the concentration of F-2,6-Bis~P in 
different tissues (Yalcin et al., 2009). In a well conducted study Herrero-Mendez and 
colleagues (2009), using RT-PCR analysis of RNA extracts from rat cortical neurons and 
astrocytes, indicated that Pfkfb3 mRNA was present in neurons as well as astrocytes. 
Importantly, the authors demonstrated that Pfkfb3 was the most abundant mRNA 
expressed in both cell types. The authors expected that if neurons contained the same 
relative abundance of Pfkfb3 mRNA as astrocytes and lower levels of the mature enzyme 
that the final concentration of PFK-2/F-2,6-Bis~Pase in neurons might be regulated post-
transcriptionally. Some studies exploring the mechanism of such proteasomal degradation 
revealed that Pfkfb3, contains a KEN box that starts at position 142 (Pesin and Orr-Weaver, 
2008; Herrero-Mendez et al., 2009). This motif targets proteins for ubiquitylation by the 
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anaphase-promoting complex/cyclosome when bound to its activator CDH1 (Pesin and 
Orr-Weaver, 2008). Interestingly, CDH1 silencing in neurons induced PFK-2/F-2,6-Bis~Pase 
accumulation and as expected increased the rate of glycolysis.  
Fructose-1,6-Bis~P is split by brain aldolase to glyceraldehyde-3-phosphate (Gal-3~P) and 
dihydroxyacetone phosphate (DHAP). DHAP is the common substrate for both 
glyceraldehyde-3-phosphate dehydrogenase and triose phosphate isomerase. One important 
point to comment is the equilibrium between DHAP and Gal-3~P maintained by the action 
of triose phosphate isomerase. In brain, the equilibrium favors accumulation of DHAP. 
After this reaction step, glycolysis in the brain proceeds through the usual biochemical 
reactions to produce pyruvate (Berg et al., 2006). 
As we have been discussing throughout the chapter neurons use glucose basically to 
maintain their antioxidant balance status. In order to do this, neurons have to downregulate 
glycolysis. Under this situation one the question is raised: Where does glucose go to be 
further metabolized? To answer this question we need to remember that pentose-phosphate 
pathway (PPP) uses G-6~P as substrate and that PPP is metabolic linked to glycolysis. One 
interesting, however somehow surprising, observation made by different laboratories is the 
fact that, in contrast to astrocytes, neurons do not display increased glycolytic rate upon 
mitochondrial inhibition as one could expect (Bolanos et al., 2008; Bolanos et al., 2010), but 
instead these neuronal cells entry into cell death program. These results lead us to assume 
that the increased glycolytic rate in astrocytes served to preserve cells from ATP depletion 
and cell death, most probably because glycolytic ATP was used to drive the reverse activity of 
ATP synthase to maintain the mitochondrial membrane potential (Nehlig and Coles, 2007; 
Bolanos et al., 2010; Cunnane et al., 2011). On the other hand, such treatment caused neuronal 
ATP depletion and apoptotic cell death (Nehlig and Coles, 2007). Based on all facts presented 
so far one can hypothesize that neurodegenerative diseases (including Alzheimer’s Disease 
and Huntington’s Disease) may present a diminished neuronal glycolytic activity (Oliveira et 
al., 2007). Data in support of this hypothesis will be discussed later. 
Accumulated evidence suggest that in neurons a significant proportion of G-6~P is directed 
towards the PPP (Bolanos et al., 2008). Besides its role at supplying ribose-5-phosphate for 
nucleic acid biosynthesis, glucose oxidation through the PPP is a major component of the 
cytosolic NADPH regenerating cell machinery (Nelson and Cox, 2004; Bolanos et al., 2008). 
The rate-limiting step in PPP activity is catalyzed by glucose-6-phosphate dehydrogenase, 
which oxidizes G-6~P into 6-phosphogluconate, conserving the redox energy as NADPH. Next, 
6-phosphogluconate is further oxidized by 6-phosphogluconate dehydrogenase, which also 
conserves redox energy in the form of NADPH (Nelson and Cox, 2004; Bolanos et al., 2008).  
It is important to note: NADPH is a necessary cofactor in the regeneration of reduced 
glutathione and for the reductive reactions for lipid biosynthesis. This mechanism is not 
exclusive for neurons it also operates in astrocytes which have high concentrations of 
glutathione due to their high activity of γ-glutamyl cysteine synthetase. This enzyme 
catalyzes the rate-limiting step in glutathione synthesis providing a metabolic scenario to 
build a robust antioxidant system (Heales and Bolanos, 2002). As neurons have rather low 
concentrations of glutathione, and low activity of γ-glutamyl cysteine synthetase there are 
compelling evidence that glucose entry in the PPP is important to regenerate glutathione 
and provide an effective defense mechanism against oxidative stress. 
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The energy output and oxygen consumption in adult brain are associated with high levels of 
enzyme activity in the tricarboxylic acid cycle (TCA). The TCA is organized into a 
supramolecular complex that interacts with mitochondrial membranes and the electron 
transport chain (Berg et al., 2006). Therefore, mitochondria have a central role for the 
energetic metabolism, their main function is oxidation of acetyl-coenzyme A derived from 
carbohydrates, amino-acids and fatty acids to produce ATP (Nelson and Cox, 2004). These 
organelles provide energy for a plethora of cellular processes and the highest number of 
mitochondria is present in organs demanding the most of energy, such as brain, liver and 
muscles.  
Actually, the processes responsible for energy production are recognized as oxidative 
phosphorylation which is coupled to the electron transport chain (ETC). The ETC is a set of 
five protein complexes sitting on the inner mitochondrial membrane. Three protein 
complexes (complex I, III and IV) work as a proton pump transferring protons through the 
membrane into the intermembrane space. Chemiosmotic theory predicts that most of the 
ATP synthesis comes from the electrochemical gradient across the inner membranes of 
mitochondria by ATP synthase. Energy saved in ATP is used in synaptic ion homeostasis 
and phosphorylation reactions. ATP is essential for the excitability and survival of neurons, 
oxidative phosphorylation is involved in synaptic signaling and is related to changes of 
neuronal structure and function. 
The major role is given to complex I (NADH dehydrogenase [ubiquinone]) in controlling 
mitochondrial oxidative phosphorylation; its malfunctioning can result in mitochondrial 
dysfunction.(Davey et al., 1998; Hroudova and Fisar, 2011). Thus, many mitochondrial 
diseases originate from complex I deficiencies. 
In adult brain, the enzyme succinate dehydrogenase (SDH), which catalysis the oxidation of 
succinate to fumarate, is tightly bound to mitochondrial inner membrane. In brain, SDH 
may also have a regulatory role when its steady state is disturbed. Important to note that the 
levels of succinate and isocitrate in brain tissue are little affected by changes in the flux of 
the TCA, as long as proper glucose supply is available. The highly unfavorable free-energy 
change of the malate dehydrogenase reaction is bypassed by the very rapid removal of 
oxaloacetate, which is maintained at low concentrations under steady-state conditions 
through the condensation reaction with acetyl-coenzyme A (Berg et al., 2006); Nelson and 
Cox, 2004). 
3. Energetic metabolism deficit in Huntington’s Disease  
Huntington´s Disease patients face pronounced weight loss, despite sustained caloric intake, 
which was a first indication that alterations in energetic metabolism could play a role in 
Huntington´s Disease pathogenesis (O’Brien et al., 1990). In agreement with this hypothesis, 
Huntington´s Disease patients exhibit alterations in cerebral glucose consume, lactate levels, 
and mitochondrial enzymes activity involved in glucose metabolism. Moreover, ATP 
depletion was directly demonstrated in Huntington´s Disease brain tissue (Mochel et al., 
2010a). Thus far, various mechanisms underlying energy deficit in Huntington´s Disease 
brain have been identified, including impaired oxidative phosphorylation (Milakovic and 
Johnson, 2005), altered oxidative stress (Tabrizi et al., 1999), impaired mitochondrial calcium 
handling (Lim et al., 2008), abnormal mitochondria trafficking (Li et al., 2010), and 
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deregulation of the transcriptional coactivator PPARǄ coactivator-1ǂ (PGC-1ǂ), which is a 
crucial factor of mitochondrial biogenesis (Cui et al., 2006), and decreased glycolysis 
(Powers et al., 2007). 
3.1 Glucose levels are reduced in Huntington’s Disease patient’s brain 
Positron emission tomography (PET) studies revealed that glucose metabolism in the basal 
ganglia and cerebral cortex is markedly reduced in Huntington´s Disease patients (Kuwert 
et al., 1990; Andrews and Brooks, 1998). Moreover, the decrease in glucose metabolism is 
specific to cortical areas, caudate and putamen, and starts in the asymptomatic phase of the 
disease (Kuhl et al., 1985). Regardless of the severity of symptoms and despite apparent 
shrinkage of brain tissue, glucose utilization appears normal throughout the rest of the brain 
of Huntington´s Disease patients (Kuhl et al., 1985).  
Furthermore, studies performed in presymptomatic Huntington´s Disease gene carriers 
revealed a pattern of cerebral metabolism characterized by relative increases in thalamic, 
occipital, and cerebellar glucose metabolism, despite reduced caudate and putamen 
metabolism. Following Huntington´s Disease symptoms appearance, this pattern was 
altered as thalamic metabolism, which was previously elevated, was reduced (Feigin et al., 
2007). These data highlights the importance of the region specific alterations in glucose 
metabolism for Huntington´s Disease pathology. 
Interestingly, a recent report supports the idea that the hypothalamus, but not the basal 
ganglia, is the brain region responsible for the metabolic abnormalities that take place in 
Huntington´s Disease (Hult et al., 2011). Selective hypothalamic expression of a short 
fragment of mutant huntingtin was sufficient to recapitulate the glucose metabolic 
disturbances that occur in Huntington´s Disease patients. In addition, selective 
hypothalamic inactivation of the mutant huntingtin gene prevented the development of the 
metabolic phenotype in a Huntington´s Disease mouse model, BACHD mice (Hult et al., 
2011). Further studies will be important to point all the regions involved in Huntington´s 
Disease metabolic alterations. 
In addition to its role as an energetic molecule, glucose also plays a role as a signaling 
molecule. It has been demonstrated that increased intracellular glucose levels decreases 
aggregate formation and is neuroprotective in cultured cells transfected with a mutant 
huntingtin construct (Ravikumar et al., 2003). Glucose metabolism appears altered in 
Huntington´s Disease, as huntingtin transfected PC12 cells exhibit disturbed expression 
levels of four genes involved in glucose metabolism (Glut1, Pfkm, Aldolase A, and Enolase), 
as well as a reduction in cell death following over-expression of Glut1 and Pfkm (another 
key regulatory protein for glycolysis) (Kita et al., 2002). Glucose reduces phosphorylation of 
mTOR, which is a negative regulator of authophagy, and its downstream effector S6K1 
(Ravikumar et al., 2003). Thus, glucose-mediated negative regulation of mTOR could induce 
autophagy and clearance of the mutated huntingtin protein, as well as influence other 
mTOR mediated activities involving cell survival, growth, and translation of protein 
transcripts. Furthermore, glucose can regulate Akt and GSK3, which influence cell growth 
and survival (Clodfelder-Miller et al., 2005). Importantly, Akt activation can protect against 
neuronal death (Datta et al., 1999; Kandel and Hay, 1999). Akt can also promote 
phosphorylation of mutated Htt protein, which functions to reduce Htt aggregate formation 
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and neuronal cell death, providing a protective pathway in Huntington´s Disease (Humbert 
et al., 2002; Warby et al., 2009). Highlighting the importance of Akt in Huntington´s Disease 
pathology, both NMDA and metabotropic glutamate receptor 5 receptors can increase Akt 
activation in striatal neurons from Huntington´s Disease mouse models (Gines et al., 2003a). 
These observations highlight the role of glucose as an important molecule not only for its 
energetic properties but also for its capacity to activate key molecules involved in cell 
survival and huntingtin clearance. 
3.2 Enzymes involved in energetic metabolism are altered in Huntington´s Disease 
Mutated huntingtin protein alters the function and/or expression of a number of enzymes 
involved in energetic metabolism and many of these alterations can have important 
implications in Huntington´s Disease pathology. Alteration of enzyme expression by 
mutated huntingtin may occur due to huntingtin-mediated regulation of transcriptional 
factors. For example, mutant huntingtin inhibits expression of PGC-1ǂ, which is a 
transcriptional coactivator that regulates several metabolic processes, including 
mitochondrial biogenesis and respiration (Cui et al., 2006). Mutated huntingtin may also 
alter enzyme function by incorporation and sequestration of transcriptional factors and 
enzymes into mutated huntingtin aggregates (Yamanaka et al., 2008). The enzyme 
alterations caused by mutated huntingtin can have important deleterious consequence, 
including the metabolic deficit observed in Huntington´s Disease patients.  
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and the ǂ-ketoglutarate 
dehydrogenase complex can be inactivated by long polyglutamine domains, which may 
cause a deficit in cerebral energy metabolism (Cooper et al., 1997). Further studies have 
shown that the mutated huntingtin protein alters the subcellular localization of GAPDH, 
increasing its nuclear localization in both human fibroblasts and in neurons from a 
transgenic mouse model (Mazzola and Sirover, 2001, 2002; Senatorov et al., 2003). The 
appearance of an abnormal high molecular weight form of GAPDH in fibroblast nuclei has 
also been associated with decreased glycolytic activity (Mazzola and Sirover, 2001). 
Pyruvate dehydrogenase activity is decreased in basal ganglia and this deficit was 
significantly augmented with increasing duration of illness, possibly due to a progressive 
loss of neurons in Huntington’s Disease caudate nucleus (Butterworth et al., 1985). Activities 
of the complexes II, III and IV of the electron transport chain were reduced in both 
Huntington´s Disease caudate and putamen of advanced grade (3 and 4) Huntington´s 
Disease patients (Gu et al., 1996; Browne et al., 1997). It has been shown that lactate 
concentration is increased in the basal ganglia and the occipital cortex of Huntington´s 
Disease patients (Jenkins et al., 1993; Jenkins et al., 1998). The lactate itself is not thought to 
be a neurotoxic metabolite, but may represent a marker for energetic changes such as 
reduced ATP production and excitotoxicity, which may have a direct effect on neuronal 
function and survival in Huntington´s Disease. 
A number of studies have shown that the activity of transglutaminase 2, an enzyme 
primarily known for cross-linking proteins, is increased in Huntington´s Disease affected 
brain areas and that transglutaminase 2 causes an increase in huntingtin aggregation 
(Karpuj et al., 1999; Lesort et al., 1999; Karpuj et al., 2002). The most compelling evidence for 
a role of transglutaminase 2 in Huntington´s Disease is provided by the work of 
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Mastroberardino et al. (2002). These studies reported a reduction in neuronal cell death, 
improved behavior and prolonged survival in R6/1 X transglutaminase 2-/-, as compared to 
R6/1 X transglutaminase 2+/+. In addition to affecting huntingtin aggregation, increased 
transglutaminase 2 activity in Huntington´s Disease caudate may contribute to 
mitochondrial dysfunction by incorporating aconitase into inactive polymers and 
dramatically decreasing aconitase activity (Kim et al., 2005).  
3.3 Mitochondrial deficit in Huntington´s Disease 
Studies published so far suggest that mitochondrial defects play a major role in 
Huntington´s Disease etiology, underlined by decreased mitochondrial biogenesis, oxidative 
stress, ATP deficit, increased apoptosis, and, ultimately, a central and peripheral energy 
deficit (Browne and Beal, 2004). 
Degenerated mitochondria have been detected in the striatum of symptomatic Huntington´s 
Disease mice (R6/2, R6/1, N171-82Q, and Hdh150CAG mice) and could be detected before 
other neuronal pathological changes and concomitant with symptom onset (Yu et al., 2003). 
These degenerating mitochondria exhibit swelling, disruption of the cristae and 
mitochondrial membranes, and eventual condensation and lysosomal engulfment. 
Interestingly, this study shows that neuronal cell death aspects due to motichondrial 
alterations varied among different Huntington´s Disease mouse models (Hickey and 
Chesselet, 2003; Yu et al., 2003).  
Mutated huntingtin protein destabilizes mitochondrial Ca2+ regulation (Panov et al., 2002; 
Choo et al., 2004). Mitochondrial Ca2+ abnormalities occur early in Huntington´s Disease 
pathogenesis and appear to be caused by a direct effect of mutant huntingtin, as incubation 
of normal human lymphoblast mitochondria with a fusion protein containing a long 
polyglutamine repeat recapitulates the mitochondrial calcium defect observed in 
Huntington´s Disease (Panov et al., 2002). Further studies have also demonstrated that the 
huntingtin protein binds to the outer membrane of mitochondria from human 
neuroblastoma cells and from cultured striatal cells from WT and transgenic mice (Choo et 
al., 2004). Moreover, binding of mutated huntingtin protein, but not of wild type, increases 
sensitivity to calcium-induced opening of the mitochondrial permeability transition (MPT), 
leading to the release of cytochrome c in normal liver mitochondria (Choo et al., 2004). 
Mitochondria play an important role in buffering cytoplasmic calcium and increased 
neuronal calcium modifies mitochondrial ATP production by uncoupling oxidative 
phosphorylation (Nicholls, 2009). Calcium overload may result in discharge of the 
mitochondrial membrane potential, opening of the MPT pore, release of cytochrome c, and 
activation of cell death pathways (Nicholls, 2009). Mutated huntingtin protein causes 
sensitization of both the NMDA receptor and the inositol-1,4,5-triphosphate (IP3) receptor, 
increasing entrance of extracellular Ca2+ and the release of Ca2+ from intracellular stores, 
respectively (Chen et al., 1999; Sun et al., 2001; Tang et al., 2005). The final result is an 
increase in intracellular Ca2+ levels. The role of NMDA receptors on mitochondrial 
biogenesis has been further characterized, as the reduced mitochondrial ATP levels and 
decreased ATP/ADP ratio found in mutant Htt-containing striatal cells is normalized by 
blocking NMDA receptor-mediated calcium influx (Seong et al., 2005). Moreover, 
mitochondria isolated from both lymphoblasts of Huntington´s Disease patients and brains 
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of transgenic mice have a reduced membrane potential and depolarize at lower Ca2+ 
concentrations than control mitochondria (Panov et al., 2002).  
Thus, data obtained so far points to a close relationship between mitochondria deficit and 
NMDA-mediated excitotoxicity. The glutamatergic system plays a substantial role in 
neuronal cell death and there are consistent data implicating NMDA receptor activation 
with the excitotoxic neuronal loss that takes place in Huntington´s Disease (Zeron et al., 
2002; Schiefer et al., 2004). Selective depletion of NMDA receptors has been found in 
Huntington´s Disease striatum, suggesting that neurons expressing NMDA receptors are 
preferentially vulnerable to degeneration (Dure et al., 1991). Prior to the identification of the 
genetic mutation responsible for Huntington´s Disease, a Huntington´s Disease mouse 
model was developed by the introduction of quinolinic acid, which is an NMDA receptor 
agonist that produces excitotoxic striatal lesions that closely resemble those seen in 
Huntington´s Disease brain (Beal et al., 1986). Moreover, some studies suggest that the 
sensitization of the NMDA receptor containing the subunit NR1/NR2B by the mutated Htt 
protein is responsible for causing the selective cell death of the medium sized spiny neurons 
present in the striatum, since these neurons express high level of this NMDA receptor 
subtype (Chen et al., 1999; Zeron et al., 2001).  
Mitochondrial toxins that deplete ATP production can also mediate excitotoxic processes 
(Schulz et al., 1996; Browne and Beal, 2002). Systemic administration of 3-nitropropionic 
acid, which is a mitochondrial toxicant that inhibits succinate dehydrogenase, results in 
striatum lesions similar to those observed in Huntington´s Disease (Wullner et al., 1994). 
Nevertheless, 3-nitropropionic acid and malonate lesions can be prevented by NMDA 
antagonists, such as MK-801 and memantine (Wullner et al., 1994). Taken together these 
observations suggest that mitochondrial-mediated excitotoxicity is promoted by secondary 
mechanisms involving glutamate receptors. It has been shown that omission of glucose, 
exclusion of oxygen, or inclusion of inhibitors of oxidative phosphorylation or of the 
sodium/potassium pump, enables glutamate to express its neurotoxic effects via NMDAR 
(Novelli et al., 1988; Henneberry et al., 1989; Zeevalk and Nicklas, 1991). Thus, in a context 
of reduced intracellular energy levels an otherwise harmless amount of glutamate becomes 
toxic.  
Studies performed with Huntington´s Disease transgenic models have implicated decreased 
transcription of genes regulated by cyclic adenosine 3′,5′-monophosphate (cAMP) 
responsive element (CRE) binding protein (CREB) to Huntington´s Disease pathology 
(Luthi-Carter et al., 2000; Shimohata et al., 2000; Steffan et al., 2000; Nucifora et al., 2001; 
Wyttenbach et al., 2001). These genes include brain derived neurotrophic factor (BDNF) 
(Zuccato et al., 2001) and a host of others involved in diverse processes ranging from 
neurotransmission (Bibb et al., 2000; Luthi-Carter et al., 2000) to cholesterol metabolism 
(Sipione et al., 2002).  
Reduced CREB dependent transcription of BDNF is a robust feature of Huntington´s 
Disease pathophysiology. By grades II and III of the disease, BDNF protein and mRNA 
levels in frontoparietal cortex are halved, and this effect can be mimicked by expressing full-
length human mutant huntingtin in a rat CNS parental cell line (Ferrer et al., 2000; Zuccato 
et al., 2001). Reduced levels of cortical and striatal BDNF have been demonstrated in 
multiple mouse models of Huntington´s Disease expressing mutant Huntingtin (including 
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R6/2, N171-82Q, Hdh, and YAC-72 lines) (Luthi-Carter et al., 2000; Zuccato et al., 2001; 
Luthi-Carter et al., 2002; Gines et al., 2003b). Importantly, the diminished CREB-mediated 
gene transcription appears to be linked to energy impairment and deficient cAMP, which 
has been shown to be decreased in the cerebral spinal fluid of symptomatic Huntington´s 
Disease patients (Sawa et al., 1999). Furthermore, PC12 cells stimulated with forskolin, 
which activates adenylyl cyclases to produce cAMP from ATP, exhibit ameliorated mutant 
huntingtin-fragment induced phenotypes, further supporting the hypothesis that low levels 
of cAMP might be implicated in Huntington´s Disease pathology (Wyttenbach et al., 2001). 
Levels of both cAMP and CRE-signaling are decreased prior to Huntington´s Disease 
symptoms in HdhQ111 mice (Gines et al., 2003b). These data suggest that mutant huntingtin 
might lead to an early metabolic deficit that amplifies the disease cascade by altering cAMP-
dependent processes, including CRE-mediated gene transcription (Gines et al., 2003b).  
4. Treatment options for the metabolic deficit 
The presence of the mutated huntingtin gene can be detected early in life which makes 
substrates capable of slowing disease progression an attracting therapeutic tool. A number 
of energy-related therapeutic approaches have been used in preclinical models and/or 
Huntington´s Disease patients, such as coenzyme Q10, creatine, antioxidant therapies, 
anaplerotic therapies, and PGC-1ǂ agonists. 
Creatine is an important energy molecule in the brain (O'Gorman et al., 1996). Creatine 
administration increases brain concentrations of phosphocreatine and inhibits activation of 
the MPT, both of which may exert neuroprotective effects (Hemmer and Wallimann, 1993; 
O'Gorman et al., 1996). Moreover, creatine appears to be neuroprotective in a rodent 
mitochondrial toxin model via enhancing cerebral energy metabolism (Koroshetz et al., 
1997; Matthews et al., 1998). The R6/2 mice exhibit lower levels of creatine and ATP in the 
brain (Dedeoglu et al., 2003). In addition, pre-symptomatic dietary creatine supplementation 
extends survival in the R6/2 and N171–82Q transgenic Huntington´s Disease mice while 
significantly improving the clinical and neuropathological phenotype (Ferrante et al., 2000; 
Andreassen et al., 2001). Creatine supplementation in symptomatic R6/2 mice also has 
clinical benefits (Dedeoglu et al., 2003). However, so far, clinical trials have demonstrated no 
substantial benefit for creatine administration to Huntington´s Disease patients (Verbessem 
et al., 2003; Tabrizi et al., 2005). One year of creatine intake, at a rate that can improve 
muscle functional capacity in healthy subjects and patients with neuromuscular disease, did 
not improve functional, neuromuscular, and cognitive status in patients with stage I to III 
Huntington´s Disease (Verbessem et al., 2003). Even the low levels of cerebral creatine and 
phosphocreatine observed in these previous studies have been disputed, as more recent 
studies in which in vivo concentrations of brain metabolites were preserved found increased 
brain levels of creatine and phosphocreatine in the same mouse model of Huntington´s 
Disease used in previous studies (Tkac et al., 2007; Mochel et al., 2010a). Thus, it is still 
unclear whether creatine has a clinical benefit to Huntington´s Disease patients.  
Q10 is an antioxidant and promoter of respiratory chain function that has also been tested as 
a treatment for Huntington´s Disease. Oral administration of Q10 ameliorates elevated 
lactate levels seen in the cortex of Huntington´s Disease patients, an effect that is reversible 
on withdrawal of the agent (Koroshetz et al., 1997). In addition, combination of Coenzyme 
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Q10 and creatine produces additive neuroprotective effects in reducing striatal lesion 
volumes produced by chronic subcutaneous administration of 3-NP to rats, improves motor 
performance, and extends survival in the transgenic R6/2 Huntington´s Disease mice (Yang 
et al., 2009). However, one large-scale study assessing the potential neuroprotective effects 
of coenzyme Q10 revealed that, at the tested dosages, Q10 produced no significant slowing in 
functional decline in early Huntington´s Disease (Huntington Study Group, 2001).  
Other antioxidants, such as ascorbate and BN82451, have been shown to improve motor 
performance and survival of R6 mice (Klivenyi et al., 2003; Rebec et al., 2003). The level of 
ascorbate is significantly diminished in the striatum of Huntington´s Disease mouse models, 
which highlights the importance of studying the effect of ascorbate supplementation to treat 
Huntington´s Disease (Rebec et al., 2002; Dorner et al., 2007). However further studies will 
be necessary to determine whether either ascorbate or other antioxidant is capable of 
slowing Huntington´s Disease progression in patients.  
A decrease in branched-chain amino acid (BCAA) levels has been observed in the plasma of 
Huntington´s Disease patients (Mochel et al., 2007). Decreased BCAA levels might occur to 
compensate the energetic deficit observed in Huntington´s Disease, which is caused by 
impaired glycolysis, citric acid cycle and/or oxidative phosphorylation, as earlier described 
in this chapter (Tabrizi et al., 1999; Browne and Beal, 2004; Milakovic and Johnson, 2005). 
Based on this hypothesis, a short-term therapeutic clinical trial was performed using 
triheptanoin, a triglyceride containing seven carbon fatty acids that is metabolized to acetyl-
CoA and propionyl-CoA, which is an anaplerotic compound that is a precursor of the citric 
acid cycle intermediate, succinate (Mochel et al., 2010b). This study shows that triheptanoin 
therapy can improve peripheral energy metabolism in Huntington´s Disease patients, and in 
particular oxidative phosphorylation in skeletal muscle (Mochel et al., 2010b). However, the 
benefit of anaplerotic approaches to the brain energy metabolism remains to be established.  
Peroxisome proliferator-activated receptor (PPAR)Ǆ is a member of the nuclear hormone 
receptor family of ligand-activated transcription factors (Rosen and Spiegelman, 2001). 
PPARǄ is the target of the insulin-sensitizing thiazolidinediones (TZDs) drugs used to treat 
type II diabetes and recent studies suggest that treatment of insulin resistance with a PPARǄ 
agonist retards the development of Alzheimer’s Disease (Watson and Craft, 2003; Watson et 
al., 2005). There is evidence suggesting that PPARǄ agonists are neuroprotective and 
increase mitochondrial function (Schutz et al., 2005; Hunter et al., 2007). Moreover, oral 
treatment with rosiglitazone, which is a thiazolidinedione drug, induces mitochondrial 
biogenesis in mouse brain (Strum et al., 2007). Interestingly, a significant defect in the 
PPARǄ signaling pathway has been found in mutant huntingtin-expressing cells, as 
compared to cells expressing wild-type huntingtin protein (Quintanilla et al., 2008). In 
addition, pretreatment of mutant huntingtin-expressing cells with rosiglitazone avoids the 
loss of mitochondrial potential, mitochondrial calcium deregulation, and oxidative stress 
overproduction in response to intracellular calcium overload (Quintanilla et al., 2008). 
Rosiglitazone also increases mitochondrial mass levels, suggesting a role for the PPARǄ 
pathway in mitochondrial function in striatal cells (Quintanilla et al., 2008). PPARǄ protein 
levels are decreased in the brain and peripheral tissue of R6/2 mice and in lymphocytes of 
Huntington´s Disease patients, probably due to a decrease in transcription as well as 
recruitment of PPARǄ protein to huntingtin aggregates (Chiang et al., 2010). R6/2 mice 
treatment with TZD results in beneficial effects on energy deficiency and on several major 
www.intechopen.com
 
Huntington’s Disease — Core Concepts and Current Advances 
 
334 
Huntington´s Disease phenotypes, decreasing weight loss, lessening motor deterioration, 
reducing mutant huntingtin aggregate formation, improving the reduced levels of two 
neuroprotective factor, Bcl-2 e BDNF, and increasing mouse life span (Chiang et al., 2010). 
Moreover, the protective effects described above appear to have been exerted, at least 
partially, via direct activation of PPARǄ in the brain (Chiang et al., 2010). 
Peroxisome proliferator-activated receptor-Ǆ coactivator (PGC)-1ǂ, which is a potent co-
activator of PPARǄ transcriptional coactivator, is a member of a family of transcription 
coactivators that plays a central role in the regulation of cellular energy metabolism and 
stimulates mitochondrial biogenesis, participating in the regulation of both carbohydrate 
and lipid metabolism (Liang and Ward, 2006). PGC-1ǂ knockout mice exhibit striatum 
lesions resembling Huntington´s Disease, which was first evidence that this molecule could 
be involved in Huntington´s Disease pathology (Lin et al., 2004). Further studies have 
demonstrated that downregulation of PGC-1ǂ in Huntington´s Disease striatum affects 
mitochondrial energy metabolism, possibly by impairing oxidative phosphorylation (Cui et 
al., 2006). Moreover, over-expression of exogenous PGC-1ǂ in Huntington´s Disease striatal 
neurons was protective against 3-NP treatment (Weydt et al., 2006). Decreasing levels of 
PGC-1ǂ were shown to parallel markers of mitochondrial dysfunction with disease 
progression in Huntington´s Disease patients (Kim et al., 2010). Of note, PGC-1ǂ 
polymorphisms in Huntington´s Disease patients may modify Huntington´s Disease onset 
age (Taherzadeh-Fard et al., 2009). Interestingly, it has been shown that mutated huntingtin 
protein can promote transcripition repression of PGC-1alpha (Cui et al., 2006). Mutant 
huntingtin represses PGC-1ǂ gene transcription by associating with the promoter and 
interfering with the CREB/TAF4-dependent transcriptional pathway (Cui et al., 2006). These 
data support a link between transcriptional deregulation and mitochondrial dysfunction in 
Huntington´s Disease.  
Resveratrol is a polyphenol that increases the activity of SIRT1, which is an activator factor 
capable of increasing PGC-1ǂ activity and mitochondrial biogenesis, as evidenced by 
increased oxidative-type muscle fibers, enhanced resistance to muscle fatigue, and increased 
tolerance to cold observed in mice treated with resveratrol (Lagouge et al., 2006). Repeated 
treatment with resveratrol for a period of 8 days beginning 4 days prior to 3-nitropropionic 
acid administration, which induces symptoms similar to Huntington´s Disease, significantly 
improves the 3-nitropropionic acid-induced motor and cognitive impairment (Kumar et al., 
2006). When tested in the context of a transgenic mouse model of Huntington´s Disease, 
resveratrol increased PGC-1ǂ mRNA levels and had protective effects in peripheral tissues, by 
reducing vacuolation in the brown adipose tissue and decreasing elevated blood glucose levels 
(Ho et al., 2010). However, there was no improvement of motor performance, weight loss, 
striatal atrophy and survival in Huntington´s Disease transgenic mice treated with resveratrol, 
which was consistent with no increase in PGC-1ǂ mRNA levels in the striatum (Ho et al., 
2010). Thus, resveratrol appears to protect against the peripheral energetic deficit in 
Huntington´s Disease, but it is not effective to alleviate CNS Huntington´s Disease pathology.  
As stated previously, transglutaminase 2 activity appears to be increased in Huntington´s 
Disease, leading to huntingtin aggregation and mitochondrial aconitase inhibition (Karpuj et 
al., 1999; Lesort et al., 1999; Kim et al., 2005). Based on these studies, cystamine, which is a 
drug capable of inhibiting transglutaminase, was tested as a therapeutic tool to treat 
Huntington´s Disease. Cystamine treatment prolongs the lifespan and reduces associated 
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tremor and abnormal movements in a Huntington´s Disease transgenic mice, possibly in 
part due to inhibition of transglutaminase 2 activity (Dedeoglu et al., 2002; Karpuj et al., 
2002). However, cystamine does not inhibits transglutaminase 2 specifically, which might 
invalidate its therapeutic use (Jeitner et al., 2005). In addition to cystamine, there are a 
number of other transglutaminase inhibitors that have been tested in Huntington´s Disease, 
such as a set of irreversible peptidic inhibitors, the allosteric reversible small-molecule 
hydrazides, and inhibitors that bind to the guanosine triphosphate (GTP) binding site 
(Duval et al., 2005; Lai et al., 2008). However, each of these compounds was found to be 
inadequate for in vivo testing because of a general lack of selectivity or poor cellular potency 
(Schaertl et al., 2010). 
Huntingtin-related proteomic studies represent an area of intense research. Proteins 
interacting with huntingtin pathological form exhibit altered patterns and metabolism. 
Mitochondrial metabolism alterations are observed in mouse models expressing various 
types of the mutated huntingtin (Browne, 2008). Moreover, knock-in mice models with 
pathogenic CAG repeats inserted into the murine homolog Hdh (e.g. HdhQ111, CAG 140, 
CAG 150) develop similar cerebral pathologies, including reduction of striatal-related 
dopamine receptor (Menalled, 2005). Protein-protein interaction studies resulted in the 
identification of many proteins interacting with huntingtin, characterizing it rather as a 
scaffolding, membrane-associated protein, involved in axonal trafficking of mitochondria 
and vesicles (Truant et al., 2006). From the large group of huntingtin-interacting proteins, 
the most research interest is focused on proteins that have a direct implication on its 
biological functions. Most of these proteins bind to the amino terminus of huntingtin near 
the polyglutamine domain (Holbert et al., 2001; Ferrier, 2002; McPherson, 2002). However, 
huntingtin-associated protein 40 (HAP40) which is affecting Rab5-mediated endosomal 
motility in complex with huntingtin, interacts with huntingtin through its carboxy-terminal 
domain (Pal et al., 2006).  
Also, the first conserved 17 amino acids in the amino-terminal huntingtin represent possible 
membrane association signal, which may influence the polyglutamine expansion (Ross, 
1997). It has been shown that specific cleavage (at the residue Arg167) and related presence of 
defined truncation at the N-terminus of huntingtin, mediate mutant huntingtin toxicity in 
Huntington’s Disease (Ratovitski et al., 2009). Association of huntingtin with the production 
of brain-derived neurotrophic factors in cortical cells, a pro-survival factor for striatal 
neurons, just completes the complexity of its functions (Zuccato et al., 2001). Thus, detailed 
studies of huntingtin-related proteome, including the role of associated proteins in 
regulation of basic signaling pathways of wild type protein and mutants/polyglutamine 
forms in Huntington´s Disease, play an important role in research for discrepancies in 
energetic metabolism in Huntington’s Disease and other neurodegenerative disorders, 
alternatively. Monospecific antibodies mapping targeting well defined epitopes on 
huntingtin and associated proteins may play a crucial role not only in basic research and 
clinical diagnostics, but also in the development of an efficient treatment for Huntington’s 
Disease.  
5. Conclusion 
Despite all the efforts to obtain a drug that could overcome the energetic deficit that takes 
place in Huntington´s Disease, no such treatment has so far been successful to treat 
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Huntington´s Disease patients. However, as huntingtin protein has multiple functions in cell 
metabolism, it is possible that combined therapeutic approaches could improve the mutated 
huntingtin-mediated energy debit and slow down Huntington´s Disease course. 
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